Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
1,800
Employees1,800
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
1,800
Employees1,800

NBIX Key Statistics

Market cap
14.14B
Market cap14.14B
Price-Earnings ratio
33.87
Price-Earnings ratio33.87
Dividend yield
Dividend yield
Average volume
1.00M
Average volume1.00M
High today
$144.83
High today$144.83
Low today
$139.72
Low today$139.72
Open price
$140.34
Open price$140.34
Volume
967.56K
Volume967.56K
52 Week high
$157.67
52 Week high$157.67
52 Week low
$84.23
52 Week low$84.23

Stock Snapshot

As of today, Neurocrine(NBIX) shares are valued at $141.83. The company's market cap stands at 14.14B, with a P/E ratio of 33.87.

During the trading session on 2025-11-23, Neurocrine(NBIX) shares reached a daily high of $144.83 and a low of $139.72. At a current price of $141.83, the stock is +1.5% higher than the low and still -2.1% under the high.

Trading volume for Neurocrine(NBIX) stock has reached 967.56K, versus its average volume of 1M.

The stock's 52-week range extends from a low of $84.23 to a high of $157.67.

The stock's 52-week range extends from a low of $84.23 to a high of $157.67.

NBIX News

Simply Wall St 14m
Distinctions Between VMAT2 Inhibitors Might Change the Case for Investing in Neurocrine Biosciences

Neurocrine Biosciences recently announced the publication of a comprehensive peer-reviewed review consolidating clinical and pharmacologic data on FDA-approved...

Distinctions Between VMAT2 Inhibitors Might Change the Case for Investing in Neurocrine Biosciences
Simply Wall St 2d
A Look at Neurocrine Biosciences Valuation After Setback in Depression Drug Trial

Neurocrine Biosciences (NBIX) recently reported results from its Phase 2 trial of NBI-1070770 for major depressive disorder. The investigational drug did not me...

A Look at Neurocrine Biosciences Valuation After Setback in Depression Drug Trial

Analyst ratings

90%

of 29 ratings
Buy
89.7%
Hold
10.3%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.